This study prospectively collected comprehensive clinical data, including: (1) baseline demographic characteristics; (2) serial measurements of laboratory parameters (e.g., white blood cell count (WBC), lymphocyte percentage (LY%), C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6)) at pre- and post-treatment intervals; and (3) Pneumonia Severity Index (PSI) scores at admission. This evidence concerns the gene IL6 and susceptibility to pneumonia measurement.